Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Hydroquinone
Overview
What is Glytone Clarifying SunVanish with Sunscreen?
Each 1 gram dose of SunVanish contains 40 mg of Hydroquinone USP, 75 mg of Octinoxate, 50 mg of Oxybenzone, 20 mg of Avobenzone, and 18.6 mg of Octocrylene in a cream base of Purified Water, Propylene Glycol, Cetearyl Alcohol, Glycerin, Sodium Lauryl Sulfate, Isopropyl Palmitate, Sodium Metabisulfite, Sorbic Acid, and Disodium EDTA.
What does Glytone Clarifying SunVanish with Sunscreen look like?
What are the available doses of Glytone Clarifying SunVanish with Sunscreen?
Sorry No records found.
What should I talk to my health care provider before I take Glytone Clarifying SunVanish with Sunscreen?
Sorry No records found
How should I use Glytone Clarifying SunVanish with Sunscreen?
SunVanish is indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.
SunVanish should be applied in the morning to the affected area and rubbed in well or as directed by your physician to achieve maximum therapeutic potential.
What interacts with Glytone Clarifying SunVanish with Sunscreen?
Sorry No Records found
What are the warnings of Glytone Clarifying SunVanish with Sunscreen?
Sorry No Records found
What are the precautions of Glytone Clarifying SunVanish with Sunscreen?
Sorry No Records found
What are the side effects of Glytone Clarifying SunVanish with Sunscreen?
Sorry No records found
What should I look out for while using Glytone Clarifying SunVanish with Sunscreen?
Prior history of sensitivity or allergic reaction to this product or any of its ingredients. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
What might happen if I take too much Glytone Clarifying SunVanish with Sunscreen?
There have been no systemic reactions from the use of topical hydroquinone in SunVanish in recommended quantities. However, treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment, but indicates caution is warranted.
How should I store and handle Glytone Clarifying SunVanish with Sunscreen?
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container [see USP].Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container [see USP].SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413SunVanish is available as follows:SizeNDC NumberNet Wt. 2 Oz. / 56 g tube 64760-401-02SunVanish should be stored at controlled room temperature 15° - 30° C (59° - 86° F). Do not expose to heat above 86° F or direct sunlight. Distributed by:Genesis Pharmaceutical, Inc.Parsippany, NJ 07054Made in U.S.A.1-800-GLYTONE (459-8663)www.glytone-usa.comRev. 062413
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation which may be prevented by the broad spectrum sunscreen agents contained in SunVanish.
Non-Clinical Toxicology
Prior history of sensitivity or allergic reaction to this product or any of its ingredients. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes.
Procainamide: Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Although this interaction is unlikely to be clinically relevant at usual ranitidine doses, it may be prudent to monitor for procainamide toxicity when administered with oral ranitidine at a dose exceeding 300 mg per day.
Warfarin: There have been reports of altered prothrombin time among patients on concomitant warfarin and ranitidine therapy. Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.
Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bioavailability. This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended.
Atazanavir: Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH. Use with caution. See atazanavir label for specific recommendations.
Delavirdine: Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H2-receptor antagonists with delavirdine is not recommended.
Gefitinib: Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium bicarbonate (dosed to maintain gastric pH above 5.0). Use with caution.
Glipizide: In diabetic patients, glipizide exposure was increased by 34% following a single 150-mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine.
Ketoconazole: Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was coadministered in a regimen to maintain a gastric pH of 6 or above. The degree of interaction with usual dose of ranitidine (150 mg twice daily) is unknown.
Midazolam: Oral midazolam exposure in 5 healthy volunteers was increased by up to 65% when administered with oral ranitidine at a dose of 150 mg twice daily. However, in another interaction study in 8 volunteers receiving IV midazolam, a 300 mg oral dose of ranitidine increased midazolam exposure by about 9%. Monitor patients for excessive or prolonged sedation when ranitidine is coadministered with oral midazolam.
Triazolam: Triazolam exposure in healthy volunteers was increased by approximately 30% when administered with oral ranitidine at a dose of 150 mg twice daily. Monitor patients for excessive or prolonged sedation.
SEE
WARNINGS
No systemic adverse reactions to hydroquinone have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued and the physician notified immediately. Sensitivity to sodium metabisulfate is a potential. See .
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).